Engflag

Agemo

Quick links to important sections

Agemo

Agemo_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Agemo

Quick Facts

Property Description
Active ingredient Polyenoicomega(ethylestersofpolyunsaturatedfattyacids)
Form Soft-gel capsules (for oral administration)
Pharmacological class Hypolipidemic drug / Lipid-regulating agent
General purpose Normalization of elevated blood triglyceride levels
Origin Purified semisynthetic derivative of natural Omega-3 PUFAs

What Type of Drug is Agemo?

Agemo is a Prescription-only medicine (Rx) classified as a Hypolipidemic drug, specifically a Lipid-regulating agent. As a Cardiovascular therapeutic agent, its fundamental role is to support lipid profile normalization in adult patients. The drug belongs to the class of Omega-3-acid ethyl ester preparations, a designation that reflects its specific, high-purity composition, differentiating it from general dietary supplements. The high concentration of the active ingredient is a distinctive feature, utilized for treating severely elevated blood fat levels.

Composition and Origin: The Essence of Polyenoicomega

The active ingredient in Agemo is Polyenoicomega(ethylestersofpolyunsaturatedfattyacids), a highly Purified, Concentrated derivative taken orally via Soft-gel capsules. This primary therapeutic substance is a semisynthetic derivative of natural Omega-3 polyunsaturated fatty acids (PUFAs). The composition involves the ethyl esters of two essential components, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA). The formulation is optimized for Oral administration and consistency, a characteristic that supports its use in scenarios requiring predictable lipid-regulating efficacy.

Agemo’s Primary Function: Why It Matters Generally

Agemo functions by influencing the body's fat metabolism, acting primarily through the reduction of hepatic triglyceride synthesis in the liver. This core mechanism is supported by the drug's ability to enhance plasma lipolysis, promoting the breakdown and clearance of fats circulating in the bloodstream. By reducing the liver’s production of these fats, Agemo serves as an integral strategy for correcting severely elevated triglyceride levels, which is a critical element in overall metabolic and Cardiovascular risk management. These Omega-3 preparations are clinically recognized for lowering very high triglyceride levels when dietary changes alone are insufficient.

What side effects are possible with Agemo?

Possible Side Effects and Safety Information

The safety profile of Agemo (Polyenoicomega) is classified based on the frequency and type of adverse reactions observed in clinical trials, as documented in official regulatory sources. This information is organized by the affected physiological system, known as System-Organ Classes (SOCs).

Common Adverse Reactions

The most frequently reported adverse reactions, classified as Common (may affect up to 1 in 10 people), primarily involve the Gastrointestinal Disorders SOC. These typically include Eructation (burping), Dyspepsia (indigestion), and Taste Perversion (an unpleasant or altered sense of taste). Other common effects may include rash and itching.

System-Organ Class Key Adverse Reactions (Common)
Gastrointestinal Disorders Eructation, Dyspepsia, Taste Perversion
Skin and Subcutaneous Rash, Pruritus
Cardiac Disorders Atrial Fibrillation (in specific populations)

Serious Adverse Reactions and Safety Constraints

Official prescribing information documents clinically significant safety considerations. The medicine may cause prolongation of bleeding time, requiring periodic monitoring for patients who are also taking anticoagulants or antiplatelet agents. Rare, but documented, serious events include Anaphylactic Reaction (a severe allergic response) and Hemorrhagic Diathesis (a tendency to bleed).

  • Cardiac Risk Pattern: There is a possible association with an increased frequency of Recurrent Atrial Fibrillation or Flutter in patients with pre-existing heart rhythm issues, observed particularly during the first few months of treatment.
  • Monitoring Requirements: The label specifies that patients with Hepatic Impairment require periodic monitoring of ALT and AST (liver enzymes). Additionally, LDL-C levels should be monitored during therapy, as increases have been observed in some patients.
  • Allergy Constraint: Because the drug is derived from fish oil, it should be used with caution in patients with a known hypersensitivity to fish or shellfish.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Agemo

The following information is strictly based on the official overdose sections of government regulatory documents, detailing the documented manifestations and mandated emergency actions for this medication.

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Overdose is generally expected to present as an exacerbation of known adverse reactions, with an increased incidence of symptoms. Manifestations primarily involve the Gastrointestinal System (vomiting, dyspepsia, constipation), and may include non-specific systemic signs (e.g., headache, rash).
Physiological systems affected Gastrointestinal System, Dermatologic System, and Central Nervous System (nonspecific effects).
Dose-related or exposure-related factors Acute overdosage is associated with a heightened severity of the drug's established clinical manifestations.
Population-specific overdose notes Official regulatory documents do not specify differential overdose risks based on age or underlying hepatic/renal condition in the dedicated overdose section.
Emergency-response statements If overdosage is suspected, the patient must immediately contact a local Poison Control Center or emergency room.
When immediate medical help is required Urgent medical attention is required upon the suspicion of overdose or the sudden development of any severe adverse clinical event.

Overdose classifications (high-level)

Classification Official Regulatory Statement
Severity classification Generally considered low acute toxicity, with no specific life-threatening toxic syndrome explicitly listed in the official overdose section.
Regulatory basis FDA Prescribing Information / EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints Management must prioritize symptomatic and supportive treatment.

Resulting overdose structure

Official overdose statements:

  • Overdose presents as an exacerbation of known clinical manifestations, mainly affecting the gastrointestinal system.
  • No specific antidote is known for this medication.
  • Treatment is mandated to be symptomatic and supportive.
  • Immediate medical assessment is required upon suspected overdosage.

Connection to the overall overdose profile

Regulatory documents define the Agemo overdose profile by the absence of a known specific antidote and a reliance on supportive care. The lack of a specific, life-threatening toxic syndrome in the labeling focuses the mandated action on immediate professional assessment and observation to manage known manifestations and prevent complications.

Therapeutic Uses of Agemo

Agemo is commonly used to address Hypertriglyceridemia in adults, a severe metabolic state where blood triglyceride levels are extremely high (typically ge 500 mg/dL). The primary therapeutic goal is to help with lipid profile normalization in situations where patients experience systemic imbalance. It is applied when systemic imbalance persists despite rigorous efforts with diet and lifestyle changes, acting as an adjunctive therapy. The medication is relevant for managing severe hypertriglyceridemia, and may be part of symptomatic management for the associated Cardiovascular Risk.

Supporting Metabolic and Cardiovascular Health

The medication plays a role in managing the broader Cardiovascular Risk profile by targeting the severe lipid imbalance. This supports patients during difficult episodes by easing distress linked to systemic imbalance. Agemo helps with managing the lipid profile, which assists with lipid profile normalization and provides supportive relief when symptoms interfere with routine activities, especially for adult patients with complicating factors like diabetes mellitus.

Quick Fact: Relevant for Managing Lipid Imbalance
Primary Therapeutic Domain Used in situations involving severely elevated blood triglyceride levels
Typical Clinical Context Used as an adjunct to diet and lifestyle changes
Patient Benefit Supports managing the overall lipid-related risk profile

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Agemo (Polyenoicomega) is strictly defined by government regulatory criteria, establishing both the allowed patient population and specific groups for whom use is contraindicated or restricted.

Populations Allowed and Prohibited

Agemo is officially indicated for adult patients with severe hypertriglyceridemia, defined as blood triglyceride levels greater than or equal to 500 mg/dL. The medicine is contraindicated in patients with a known hypersensitivity or allergy to Agemo or any of its components.

Age and Organ-Function Restrictions

Safety and effectiveness have not been established for use in pediatric patients (under 18 years of age). For older adults, no overall differences in safety have been observed. Specific caution is required for patients with hepatic impairment, necessitating periodic monitoring of liver enzyme levels during therapy.

Conditional Use and Comorbidities

Conditional use is required for patients with pre-existing Atrial Fibrillation or Flutter due to a documented possible risk of increased recurrences. Caution is also advised when Agemo is used by patients with a known fish or shellfish allergy or those concurrently taking anticoagulants, where regular coagulation monitoring is required. In pregnancy, use is conditional, advised only if the potential benefit justifies the potential risk; use during lactation is also advised with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Agemo (Polyenoicomega) as defined by government regulatory authorities.

Interaction Classification Official Regulatory Statement
Pharmacodynamic Interaction Co-administration with anticoagulants (e.g., Warfarin) or other medicines affecting coagulation (e.g., anti-platelet agents) may prolong bleeding time [Source: FDA Prescribing Information].
Metabolic Interaction (CYP) Clinically significant drug–drug interactions resulting from Cytochrome P450 enzyme inhibition are not expected [Source: NIH/FDA Regulatory Monograph].

Interaction-Related Constraints and Monitoring

Coagulation Modifiers: The official regulatory profile states that patients receiving co-treatment with anticoagulants or other drugs affecting blood coagulation must be monitored periodically for changes in coagulation parameters.

Hepatic Impairment: For patients with pre-existing hepatic impairment, Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) levels should be monitored periodically during therapy [Source: FDA Prescribing Information].

Exposure-Related Effect: The medication is documented to increase Low-Density Lipoprotein Cholesterol (LDL-C) levels in some patients, necessitating periodic monitoring of LDL-C levels [Source: FDA Prescribing Information].

Timing and Substances: The official labeling does not include mandatory time-separation requirements for dosing. The product's contraindication is limited to known hypersensitivity to omega-3-acid ethyl esters or any of the product’s components, such as fish or shellfish derivatives. The drug's interaction structure is defined primarily by its pharmacodynamic effect on hemostasis, requiring close management of coagulation parameters.

Mechanism of Action

Agemo's mechanism of action is a comprehensive pharmacological strategy that acts on core liver and vascular pathways to reduce systemic triglyceride levels. The drug's mechanism involves a multi-targeted approach that both restricts the production of fats and increases their rate of clearance from the circulation.

Inhibiting the Liver's Fat Synthesis Engine

This mechanism focuses on blocking the two primary checkpoints for hepatic lipogenesis (fat production). The active components inhibit DGAT, the enzyme that completes triglyceride assembly, while simultaneously suppressing SREBP-1c, the transcription factor that genetically instructs the liver to make fat. This dual inhibition reduces the liver's capacity to create and secrete triglyceride-rich VLDL particles into the bloodstream.

Enhancing Fat Breakdown and Systemic Clearance

Agemo promotes the catabolism (breakdown) of fats through PPAR-alpha agonism, which up-regulates the genetic machinery for fatty acid oxidation, thereby reducing the substrate pool available for new triglyceride synthesis. Complementing this, the drug increases the activity of Lipoprotein Lipase (LPL), an enzyme responsible for increasing the rate of clearance and breakdown of triglycerides already circulating in the plasma. This dual enhancement establishes a continuous process for catabolizing systemic fat.

Pharmacological Synergy and Dynamic Onset

The combined action of the two active ingredients provides mechanistic synergy by modulating multiple targets across the synthesis and clearance pathways. Because the mechanism relies heavily on genomic programming changes (e.g., PPAR-alpha activation and SREBP-1c suppression), the resulting physiological reduction in circulating triglycerides develops over weeks rather than hours, leading to a decreased concentration of circulating triglycerides.

Dosage and Administration Information

How to Use Agemo: Official Administration Guidelines

Agemo, containing the active ingredient Polyenoicomega, is used strictly as an oral medication and is administered as a soft-gel capsule. The usage protocol is established for the treatment of severely elevated blood triglyceride levels as an adjunct to diet.

Administration Scope

Feature Description
Route of administration Oral (by mouth).
Dosing schedule The standard adult daily dose is 4 grams per day (g/day), which is also the maximum dose.
Frequency pattern Daily, administered either as a single dose of 4 grams or as a divided dose of 2 grams twice per day.
Timing in relation to meals Must be taken with meals (with food) to optimize absorption.
Preparation requirements The soft-gel capsule must be swallowed whole and must not be crushed, dissolved, broken, or chewed.
Treatment Duration Intended for chronic, long-term use as a continuous daily therapy.

Special Procedural Conditions

Prior to starting Agemo, patients must be placed on an appropriate lipid-lowering diet, and this diet must be maintained throughout the entire course of therapy. For older adults, no specific, across-the-board dose adjustment is generally required by the official labeling. If a dose is missed, patients should take it as soon as they remember, unless it is almost time for the next dose; in that scenario, the missed dose should be skipped to prevent a double dose.

Connection to the Overall Use Protocol

These official instructions establish a precise, structured protocol where Agemo is used daily, indefinitely, as a mandatory adjunct to a required diet. The fixed maximum daily dose and the constraint to take the capsule whole and with food define the required conditions for the standardized administration of this medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Agemo (Polyenoicomega)

Evidence for Severe Hypertriglyceridemia

The primary clinical research involves studies examining Agemo in adult patients with very high fasting blood triglyceride levels (typically 500 mg/dL or higher). The existing evidence is largely derived from short-to-intermediate-term, randomized controlled trials (RCTs). In these studies, participants were randomly assigned to receive either Agemo or an inactive comparison substance (placebo) over several months. These studies were applied in research contexts involving patients already following a controlled, lipid-lowering diet.

Researchers primarily monitored the percentage change in fasting triglyceride concentrations from the beginning of the study to the end of the short-term observation period. The studies describe patterns observed in the research related to changes in this specific blood biomarker. The measurements focused on how triglyceride concentrations evolved in patients receiving the study medication.

Outcomes Measured in Clinical Trials

The research examined various outcomes related to systemic or functional imbalance, specifically focusing on blood fat markers. Besides triglycerides, studies also monitored changes in other components of the lipid profile, such as Total Cholesterol (TC), Very-Low-Density Lipoprotein Cholesterol (VLDL-C), and non-HDL Cholesterol. The research also monitored levels of Low-Density Lipoprotein Cholesterol (LDL-C).

Patterns were reported in some studies where the monitoring of LDL-C levels showed an increase in this marker in some patients with very high triglycerides. The evidence contributes to the broader evidence landscape by providing insight into short-term changes across several physiological markers.

Long-term Follow-up and Cardiovascular Research Context

The primary studies conducted to evaluate Agemo for high triglycerides generally have limited follow-up durations, typically monitoring patients for only about 3 to 4 months. Therefore, long-term effects are not fully established regarding the durability of the observed changes in triglyceride levels over extended periods.

In the broader class of prescription omega-3s, studies have explored the connection between lipid management and major adverse cardiovascular events (MACE), such as heart attack and stroke. However, findings were mixed when examining the combined EPA/DHA ethyl ester formulation (the active components in Agemo). The research explored long-term cardiovascular outcomes primarily using data derived from trials involving a different, single-component, highly purified EPA-only product. Regulatory evaluations noted that the evidence for the combined EPA/DHA formulation did not establish support for its use in secondary prevention following a heart attack.

Known Limitations and Research Gaps

One key limitation is that the trials for severe hypertriglyceridemia did not determine whether the use of the medicine was associated with a change in the risk of heart attack, stroke, or cardiovascular death.

Additionally, existing studies provide limited insight into outcomes related to episodic or acute changes, specifically regarding the relationship between the medicine and the risk of pancreatitis. Comparative evidence is lacking for how durable the effects are beyond the short trial windows, meaning follow-up durations were limited for understanding sustained outcomes.

Key Studies & References

  1. NIH DailyMed Drug Information: Omega-3-Acid Ethyl Esters (Summary of Pivotal Trials)
  2. Evidence and Guidelines for the Management of Hypertriglyceridemia (Authoritative clinical guideline context)

Frequently Asked Questions (FAQ)

Common questions about Agemo (FAQ)

Q: Are there any long-term health concerns associated with using Agemo?

Official research evidence for Agemo is primarily based on short-to-intermediate-term clinical trials. These studies, typically lasting only a few months, were designed to measure changes in blood fat levels. Therefore, the clinical trials conducted did not determine whether the use of the medicine was associated with a change in the risk of outcomes like heart attack or stroke.

Q: If I feel better, is it okay to stop taking Agemo?

Agemo is intended for continuous, long-term use as part of a chronic treatment plan. Regulatory documents emphasize that patients should not stop taking the medication or change their dose on their own, even if they begin to feel better. Any changes to the medication schedule are a matter for discussion with a healthcare provider.

Q: What should be done if an allergic reaction is suspected after taking Agemo?

If you suspect an allergic reaction, the official patient safety information advises seeking emergency medical help immediately. This information recommends watching for signs of a severe reaction, such as hives, swelling of the face or throat, or difficulty breathing.

Q: Can Agemo be used by people with a history of heart problems?

Official regulatory labeling includes a precaution regarding patients with pre-existing heart rhythm issues. Studies showed a possible association with an increased frequency of recurrent Atrial Fibrillation or Flutter in this population. Patients with pre-existing heart rhythm issues are subject to specific safety monitoring requirements as defined in the official prescribing information.

Q: How does Agemo affect blood pressure or heart rate?

The medicine's official safety profile notes a risk of Atrial Fibrillation (an irregular heart rhythm) in certain patient groups. However, the general adverse reaction tables from clinical studies do not commonly list a specific effect on overall blood pressure or resting heart rate.

Q: Can you take Agemo with common pain relievers like Tylenol (acetaminophen) or Advil (ibuprofen)?

Regulatory warnings advise caution if Agemo is taken alongside anti-platelet agents, a class of medication that includes products like ibuprofen (Advil). This is due to the potential for the combination to prolong bleeding time. Acetaminophen (Tylenol) is not specifically listed in the official interaction warnings.

Q: Is it normal to feel a little dizzy or tired when first starting Agemo?

Fatigue and dizziness have been reported in official studies as less common or frequency-not-defined adverse reactions for this drug class. This means they are not considered among the most frequently observed side effects.

Q: Do the side effects of Agemo generally get better or worse over time?

Official data includes an observation that certain safety events may be more frequent when treatment begins. Specifically, the risk of recurrent Atrial Fibrillation or Flutter, where observed, appeared more frequently during the first two to three months of treatment compared to an inactive substance.

Q: Can Agemo affect sleep patterns?

Insomnia (difficulty sleeping) has been reported in the adverse reaction tables for this drug class. This information is available in official regulatory documents.

Q: What is the experience of taking Agemo during pregnancy or breastfeeding, based on available research?

For pregnancy, it is not known if Agemo can harm an unborn baby. For breastfeeding, the active ingredient is known to pass into human milk, and it is also unknown if it can harm a breastfed baby. Official prescribing information advises exercising caution when the medicine is administered to a woman who is breastfeeding.

Q: Can Agemo affect mood or energy levels?

Adverse reaction tables for this drug class have included reports of effects related to mood, such as depression, anxiety, and nervousness. Fatigue has also been reported as a less common side effect in the official documents.

Q: Can Agemo be taken while drinking alcohol?

It is not known if alcohol directly affects the drug itself. However, the official warnings mention that excessive alcohol intake is a condition that can raise triglyceride levels, potentially counteracting the therapeutic goal of the medicine.

Q: Does Agemo interact with herbal supplements or vitamins?

Official drug information advises patients to inform their healthcare provider about everything they are taking. This includes all prescription and over-the-counter medicines, as well as vitamins, minerals, herbal products, and any other supplements.

Q: What is the relationship between Agemo's dose and its effectiveness?

Regulatory studies describe that the medicine induced significant changes in the amount of active fatty acid components found in the blood. These changes were described as dose-dependent, meaning they increased with the amount of medication administered, which is consistent with its mechanism for lowering triglycerides.

Q: What official bodies have approved Agemo for use?

The official documents related to Agemo's approval and safety are published or sourced by government bodies responsible for drug regulation. In the United States, these include the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) DailyMed.

Q: Is Agemo safe for people who have diabetes?

Official warnings advise managing concurrent conditions that contribute to lipid abnormalities, which includes diabetes. The official documentation includes periodic monitoring of blood markers during therapy for patients with concurrent conditions.

How should Agemo be stored and disposed of?

How to Store and Dispose of Agemo

All storage and disposal instructions for Agemo soft-gel capsules must comply strictly with official regulatory labeling to ensure product stability and safety.

Condition Requirement
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C. Do not store above 30 C and do not freeze.
Protection Keep the medicine in its original blister pack and carton to protect the capsules from light and moisture.
Child Safety Keep this medicine out of the sight and reach of children.
Disposal Dispose of any unused product in accordance with local requirements. Do not throw medicines away via wastewater or household trash.

Adherence to these conditions is required to maintain the integrity of the Polyenoicomega active ingredient until the labeled expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Agemo found in:

A-Z Index: